SM
LEXXW

Sabby Management’s Lexaria Bioscience Warrant LEXXW Stock Holding History

Sabby Management’s Portfolio LEXXW Stock Details LEXXW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-209,979
Closed -$42K – 75
2023
Q3 		$42K Sell
209,979
-30,227
-13% -$7.23K 0.03% 66
2023
Q2 		$52.8K Sell
240,206
-22,992
-9% -$7.94K 0.04% 70
2023
Q1 		$150K Buy
263,198
+43,385
+20% +$23.9K 0.13% 49
2022
Q4 		$87.9K Sell
219,813
-65,547
-23% -$32.9K 0.08% 78
2022
Q3 		$699K Sell
285,360
-58,174
-17% -$44.7K 0.88% 27
2022
Q2 		$240K Sell
343,534
-82,349
-19% -$72.1K 0.16% 65
2022
Q1 		$383K Buy
425,883
+17,069
+4% +$19.2K 0.06% 72
2021
Q4 		$613K Buy
408,814
+75,843
+23% +$148K 0.09% 100
2021
Q3 		$699K Sell
332,971
-68,275
-17% -$168K 0.09% 105
2021
Q2 		$1.01M Buy
401,246
+110,246
+38% +$287K 0.14% 80
2021
Q1 		$695K Buy
+291,000
New +$638K 0.14% 91

Other funds holding LEXXW

BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Sabby Management's LEXXW Position: Q4 2023 in Review

Sabby Management sold out of Lexaria Bioscience Warrant (LEXXW) in Q4 2023, closing a stake of 209,979 shares — an estimated $42K sold.

Sabby Management first reported a position in LEXXW in Q1 2021 and held it in 11 quarters. The position peaked at $1.01M in Q2 2021. 3 funds tracked by Wall St. Rank hold LEXXW as of Q4 2023.

  • Sabby Management reported no remaining Lexaria Bioscience Warrant position as of Q4 2023 after selling out during the quarter.
  • Sabby Management sold 209,979 Lexaria Bioscience Warrant shares in Q4 2023, an estimated $42K.
  • Sabby Management first reported a position in Lexaria Bioscience Warrant in Q1 2021 and held it in 11 quarters.
  • Sabby Management's Lexaria Bioscience Warrant position peaked at $1.01M in Q2 2021.
  • 3 funds tracked by Wall St. Rank held Lexaria Bioscience Warrant as of Q4 2023.

Based on Sabby Management's 13F filing for Q4 2023, filed 14 Feb 2024.